# A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

> **NCT01888081** · PHASE1,PHASE2 · TERMINATED · sponsor: **Virogen Biotechnology Inc.** · enrollment: 2 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** A-dmDT390-bisFv(UCHT1) (Resimmune®)
- **RADIATION:** Ionizing Radiation

## Key facts

- **NCT ID:** NCT01888081
- **Lead sponsor:** Virogen Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2020-12
- **Final completion:** —
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)
- **Last updated:** 2016-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888081, "A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01888081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*